Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Catalyst Biosciences Stock

CBIO
US14888D2080
A2DLUK

Price

17.86
Today +/-
+0
Today %
+0 %
P

Catalyst Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Catalyst Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Catalyst Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Catalyst Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Catalyst Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Catalyst Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Catalyst Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Catalyst Biosciences’s growth potential.

Catalyst Biosciences Revenue, EBIT and net profit per share

DateCatalyst Biosciences RevenueCatalyst Biosciences EBITCatalyst Biosciences Net Income
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined-83,640 undefined-29.24 M undefined
2025e0 undefined-692,580 undefined-774,588.05 undefined
2024e0 undefined-1.26 M undefined-1.16 M undefined
2023e0 undefined-6.28 M undefined-6.2 M undefined
2022794,000 undefined-29.41 M undefined-8.24 M undefined
20217.34 M undefined-87.89 M undefined-87.93 M undefined
202020.95 M undefined-56.57 M undefined-56.24 M undefined
20190 undefined-57.28 M undefined-55.18 M undefined
201810,000 undefined-33.82 M undefined-30.06 M undefined
20171.02 M undefined-21.82 M undefined-25.51 M undefined
2016400,000 undefined-20.42 M undefined-16.95 M undefined
20151.75 M undefined-13.8 M undefined-14.76 M undefined
20141.81 M undefined-7.51 M undefined-6.61 M undefined
2013520,000 undefined-10.12 M undefined-9.97 M undefined
201257.86 M undefined-4.42 M undefined-7 M undefined
201197.64 M undefined-9.75 M undefined-8.53 M undefined
201085.71 M undefined13.12 M undefined10.9 M undefined
200925.06 M undefined-40.33 M undefined-39.4 M undefined
200820.09 M undefined-28.14 M undefined-25.66 M undefined
200711.58 M undefined-31.77 M undefined-28.07 M undefined
200627.54 M undefined-400,000 undefined-1.24 M undefined
20051.18 M undefined-29.94 M undefined-40.23 M undefined
20043.74 M undefined-24.39 M undefined-43.08 M undefined
20032.46 M undefined-20.06 M undefined-27.74 M undefined

Catalyst Biosciences Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e
22312711202585975701101002070000000
--50.00-66.672,600.00-59.2681.8225.00240.0014.12-41.24---------65.00-------
100.0050.00100.00-100.0090.9195.0096.00100.00100.00--------55.00--------
2130271019248597000000001100000000
-18-20-24-290-31-28-4013-9-4-10-7-13-20-21-33-57-56-87-29-6-10000
-900.00-1,000.00-800.00-2,900.00--281.82-140.00-160.0015.29-9.28-7.02--700.00-1,300.00--2,100.00---280.00-1,242.86-------
-25-27-43-40-1-28-25-3910-8-7-9-6-14-16-25-30-55-56-87-8-6-10-2900
-8.0059.26-6.98-97.502,700.00-10.7156.00-125.64-180.00-12.5028.57-33.33133.3314.2956.2520.0083.331.8255.36-90.80-25.00-83.33----
---------------------------
---------------------------
0.180.180.180.180.130.190.230.240.290.30.320.020.020.30.783.4211.21121.282.042.1000000
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Catalyst Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Catalyst Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Catalyst Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Catalyst Biosciences's financial health and stability.

Assets

Catalyst Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Catalyst Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Catalyst Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Catalyst Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-21-19-24-292-28-25-3910-8-7-10-6-14-16-21-30-55-56-87-8
100000112221000000000
000000000000000000000
00-11-134901720710-1020-600-18-20-4
200002-4-3-81-88-49001-202333-20
000000000000000000000
000000000000000000000
-17-19-25-26-924-28-24138-83-64-6-6-19-18-19-28-43-55-83-33
-1000-1-4-20-3-100000000000
12-26300-13-26-59-62-57390037-1-11-712794855
13-26310-12-21-310-59-564000370-11-702794955
000000000000000000000
202-2012-100-15590-14-50000
4514330401129483820000135116060490
481335-140133147682055902111106049-45
000000003000000000000
00000000000000000000-45
43-3241-281611-23281-58-250-127-18-1011-151413-22
-18.4-19.8-25.7-26.5-1119.9-30.4-24.5135-85.1-64.5-6.3-6.4-19.4-19-19.9-29-43.7-55.32-84.59-33.1
000000000000000000000

Catalyst Biosciences stock margins

The Catalyst Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Catalyst Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Catalyst Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Catalyst Biosciences's sales revenue. A higher gross margin percentage indicates that the Catalyst Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Catalyst Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Catalyst Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Catalyst Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Catalyst Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Catalyst Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Catalyst Biosciences Margin History

Catalyst Biosciences Gross marginCatalyst Biosciences Profit marginCatalyst Biosciences EBIT marginCatalyst Biosciences Profit margin
2028e-0.5 %0 %0 %
2027e-0.5 %0 %0 %
2026e-0.5 %0 %0 %
2025e-0.5 %0 %0 %
2024e-0.5 %0 %0 %
2023e-0.5 %0 %0 %
2022-0.5 %-3,703.65 %-1,038.04 %
2021-0.57 %-1,197.79 %-1,198.32 %
202056.26 %-270.05 %-268.48 %
2019-0.5 %0 %0 %
2018-0.5 %-338,200 %-300,600 %
2017-0.5 %-2,139.22 %-2,500.98 %
2016-0.5 %-5,105 %-4,237.5 %
2015-0.5 %-788.57 %-843.43 %
2014-0.5 %-414.92 %-365.19 %
2013-0.5 %-1,946.15 %-1,917.31 %
2012-0.5 %-7.64 %-12.1 %
2011100 %-9.99 %-8.74 %
2010100 %15.31 %12.72 %
200997.25 %-160.93 %-157.22 %
200896.27 %-140.07 %-127.73 %
200793.78 %-274.35 %-242.4 %
200698.33 %-1.45 %-4.5 %
200559.32 %-2,537.29 %-3,409.32 %
200494.65 %-652.14 %-1,151.87 %
200369.92 %-815.45 %-1,127.64 %

Catalyst Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The Catalyst Biosciences earnings per share therefore indicates how much revenue Catalyst Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Catalyst Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Catalyst Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Catalyst Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Catalyst Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Catalyst Biosciences Revenue, EBIT and net profit per share

DateCatalyst Biosciences Sales per ShareCatalyst Biosciences EBIT per shareCatalyst Biosciences Earnings per Share
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined-0.77 undefined
2025e0 undefined0 undefined-0.02 undefined
2024e0 undefined0 undefined-0.03 undefined
2023e0 undefined0 undefined-0.16 undefined
20220.38 undefined-13.98 undefined-3.92 undefined
20213.59 undefined-43.03 undefined-43.04 undefined
202016.38 undefined-44.24 undefined-43.98 undefined
20190 undefined-4.77 undefined-4.6 undefined
20180 undefined-3.02 undefined-2.68 undefined
20170.3 undefined-6.38 undefined-7.46 undefined
20160.51 undefined-26.18 undefined-21.73 undefined
20155.83 undefined-46 undefined-49.2 undefined
201490.5 undefined-375.5 undefined-330.5 undefined
201326 undefined-506 undefined-498.5 undefined
2012180.81 undefined-13.81 undefined-21.88 undefined
2011325.47 undefined-32.5 undefined-28.43 undefined
2010295.55 undefined45.24 undefined37.59 undefined
2009104.42 undefined-168.04 undefined-164.17 undefined
200887.35 undefined-122.35 undefined-111.57 undefined
200760.95 undefined-167.21 undefined-147.74 undefined
2006211.85 undefined-3.08 undefined-9.54 undefined
20056.56 undefined-166.33 undefined-223.5 undefined
200420.78 undefined-135.5 undefined-239.33 undefined
200313.67 undefined-111.44 undefined-154.11 undefined

Catalyst Biosciences business model

Catalyst Biosciences Inc. is a biotechnology company specializing in the development of innovative therapies for rare diseases and severe bleeding disorders. They collaborate with doctors, academics, and patient organizations to bring new treatment options to the market. Their business model is based on the development of proteins that influence the blood clotting process to prevent or reduce bleeding. They use a proprietary technology called Protease Engineering Platform (PEP) to make customized proteins. Catalyst Biosciences Inc. focuses on therapies for rare diseases such as hemophilia A and B, hemorrhagic diathesis, and other rare diseases like factor XIII deficiency or thrombasthenia. They offer a range of products, including CB 2679d, CB 813d, and CB 2679f for the treatment of hemophilia B. Catalyst Biosciences Inc. has achieved milestones and is considered one of the most promising companies in the industry. With its innovative technology and comprehensive portfolio, it has the potential for further success. Catalyst Biosciences is one of the most popular companies on Eulerpool.com.

Catalyst Biosciences SWOT Analysis

Strengths

Catalyst Biosciences Inc possesses several key strengths that contribute to its overall success and competitive advantage within the industry. These strengths include:

  • A strong portfolio of innovative and groundbreaking biopharmaceutical products
  • Extensive research and development capabilities, enabling the company to create cutting-edge solutions
  • A talented team of scientists and researchers with deep expertise in the field
  • Well-established partnerships with leading organizations in the biotech and pharmaceutical sectors
  • A strong financial position, enabling investments in new projects and opportunities
  • A solid reputation for delivering quality products and services to customers

Weaknesses

Despite its strengths, Catalyst Biosciences Inc also faces certain weaknesses that could impact its performance and hinder its growth. These weaknesses include:

  • Relatively limited market presence compared to some larger competitors
  • Dependence on a small number of key products for revenue generation
  • Limited marketing and brand awareness, potentially affecting market penetration
  • High research and development costs, leading to financial strain
  • Vulnerability to regulatory changes and industry-specific challenges

Opportunities

Catalyst Biosciences Inc can leverage various opportunities to further expand its business and maximize its market potential. These opportunities include:

  • Increasing demand for innovative and personalized biopharmaceutical solutions
  • Potential for exploration and expansion into new geographic markets
  • Growing collaborations with research institutions and academia to foster innovation
  • Advancements in technology that could enhance the company's research and development capabilities
  • Potential partnerships with larger pharmaceutical companies for distribution and commercialization

Threats

Catalyst Biosciences Inc must also be wary of various threats that could pose challenges to its operations and profitability. These threats include:

  • Intense competition from both established biotech companies and emerging startups
  • Potential for regulatory hurdles and delays in product approvals
  • Fluctuating market conditions and economic uncertainties
  • Rapid advancements in technology that may render certain products or approaches obsolete
  • Changes in healthcare policies and reimbursement mechanisms

Catalyst Biosciences valuation based on historical P/E ratio, EBIT, and P/S ratio.

Catalyst Biosciences shares outstanding

The number of shares was Catalyst Biosciences in 2023 — This indicates how many shares 2.103 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Catalyst Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Catalyst Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Catalyst Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Catalyst Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Catalyst Biosciences Stock splits

In Catalyst Biosciences's history, there have been no stock splits.

Catalyst Biosciences Stock Dividend

In 2023, Catalyst Biosciences paid a dividend amounting to 0.24 USD. Dividend means that Catalyst Biosciences distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Catalyst Biosciences provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Catalyst Biosciences’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Catalyst Biosciences's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Catalyst Biosciences Dividend History

DateCatalyst Biosciences Dividend
20221.43 undefined
201559.77 undefined

Catalyst Biosciences Stock Payout Ratio

In 2023, Catalyst Biosciences had a payout ratio of 0%. The payout ratio indicates the percentage of the company's profits that Catalyst Biosciences distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Catalyst Biosciences represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Catalyst Biosciences could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Catalyst Biosciences's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Catalyst Biosciences Payout Ratio History

DateCatalyst Biosciences Payout ratio
2028e0 %
2027e0 %
2026e0 %
2025e0 %
2024e0 %
2023e0 %
2022-36.49 %
20210 %
20200 %
20190 %
20180 %
20170 %
20160 %
2015-121.48 %
20140 %
20130 %
20120 %
20110 %
20100 %
20090 %
20080 %
20070 %
20060 %
20050 %
20040 %
20030 %
Unfortunately, there are currently no price targets and forecasts available for Catalyst Biosciences.

Catalyst Biosciences Stock Shareholders

%
Name
Stocks
Change
Date
7.02 % Lytton (Laurence W)2,667,33307/19/2023
2.04 % Renaissance Technologies LLC774,386-101,5006/30/2023
16.50 % GNI Group Ltd6,266,52107/19/2023
1.56 % JDS1 LLC590,700-540,87710/6/2022
1.29 % CCUR Holdings Inc491,700-624,16510/6/2022
1.02 % Oros (David S)388,600010/6/2022
0.71 % Geode Capital Management, L.L.C.270,03306/30/2023
0.38 % BlackRock Institutional Trust Company, N.A.146,093-13,8266/30/2023
0.38 % Acadian Asset Management LLC144,028-115,4396/30/2023
0.24 % Kynam Capital Management LP89,88606/30/2023
1
2
3
4
5
...
10

Catalyst Biosciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Biogen Stock
Biogen
SupplierCustomer0,460,180,190,620,920,53
ISU ABXIS Stock
ISU ABXIS
SupplierCustomer0,09-0,14-0,280,560,920,23
AGC Stock
AGC
SupplierCustomer-0,39-0,28-0,080,54--0,66
Pfizer Stock
Pfizer
SupplierCustomer-0,40-0,14-0,170,14-0,77-0,88
1

Catalyst Biosciences stock: Frequently Asked Questions

What values and corporate philosophy does Catalyst Biosciences represent?

Catalyst Biosciences Inc represents values of innovation, scientific excellence, and dedication to improving patient lives. With a corporate philosophy centered around advanced therapeutic solutions, the company aims to address unmet medical needs in the field of rare and severe diseases. Catalyst Biosciences Inc emphasizes a patient-centric approach, striving to develop novel therapies that provide better outcomes. By leveraging their deep understanding of protease pharmacology, the company focuses on creating next-generation medicines with enhanced safety and efficacy profiles. Through their research and development efforts, Catalyst Biosciences Inc is committed to making a lasting impact in the healthcare industry.

In which countries and regions is Catalyst Biosciences primarily present?

Catalyst Biosciences Inc is primarily present in the United States.

What significant milestones has the company Catalyst Biosciences achieved?

Catalyst Biosciences Inc has achieved several significant milestones. The company successfully developed its proprietary protease technology platform, which enables the engineering of proteases with improved therapeutic properties. Catalyst Biosciences also advanced several programs into clinical development, including CB 2679d/ISU304 for the treatment of hemophilia B and CB 2782 for the potential treatment of dry age-related macular degeneration. Moreover, the company established collaborations with leading pharmaceutical companies, such as Novartis, for the development of novel hemophilia therapies. These achievements demonstrate Catalyst Biosciences' commitment to advancing innovative therapies and its significant progress in the biopharmaceutical field.

What is the history and background of the company Catalyst Biosciences?

Catalyst Biosciences Inc, headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare and life-threatening hematologic and complement-mediated disorders. Founded in 2002 as Targesome Inc, the company was later renamed Catalyst Biosciences in 2006. Catalyst Biosciences has a rich history of scientific innovation and collaboration, aiming to address unmet medical needs. With a dedicated team of experienced researchers and scientists, Catalyst Biosciences is committed to developing safe and effective therapies that can significantly improve the lives of patients dealing with rare diseases.

Who are the main competitors of Catalyst Biosciences in the market?

The main competitors of Catalyst Biosciences Inc in the market include BioMarin Pharmaceutical Inc, Sangamo Therapeutics Inc, and UniQure NV.

In which industries is Catalyst Biosciences primarily active?

Catalyst Biosciences Inc primarily operates in the biotechnology and pharmaceutical industries.

What is the business model of Catalyst Biosciences?

The business model of Catalyst Biosciences Inc. entails the development and commercialization of therapeutics for the treatment of rare and life-threatening diseases. The company focuses on engineering proteases for precision and potent activity in order to address unmet medical needs. Catalyst Biosciences utilizes its proprietary protease platform technology to design novel small molecules and biologics that target specific diseases. By leveraging its expertise in protease engineering, the company aims to provide innovative and effective treatment options for patients in various therapeutic areas, including hematology, rare bleeding disorders, and complement-related diseases.

What is the P/E ratio of Catalyst Biosciences 2024?

The Catalyst Biosciences P/E ratio is -32.33.

What is the P/S ratio of Catalyst Biosciences 2024?

The Catalyst Biosciences P/S ratio is 0.

What is the AlleAktien quality score of Catalyst Biosciences?

The AlleAktien quality score for Catalyst Biosciences is 3/10.

What is the revenue of Catalyst Biosciences 2024?

The revenue cannot currently be calculated for Catalyst Biosciences.

How high is the profit of Catalyst Biosciences 2024?

The expected Catalyst Biosciences profit is -1.16 M USD.

What is the business model of Catalyst Biosciences

Catalyst Biosciences Inc is a publicly traded biopharmaceutical company based in Southern California that focuses on developing innovative therapies for severe, rare diseases. The company utilizes its proprietary platform technologies to develop protein therapeutics that regulate hemostasis, treat immune disorders, and specifically target cancer cells. One of the main divisions of Catalyst Biosciences is its hemostasis products, including its Kringle-Designed Targets (KDTs) used in the treatment of hemophilia and other bleeding disorders. These therapeutics are recombinant proteins specifically designed to modulate the body's coagulation cascade before it can lead to uncontrolled bleeding or thrombosis. Catalyst Biosciences also has a successful partnership program with Pfizer Inc. for the development of factor VIIa therapeutics for the treatment of hemophilia patients. Catalyst Biosciences also has a division for precision medicine-based immunotherapeutics. These therapeutics aim to manipulate the immune system to treat inflammatory and autoimmune diseases. The company has developed several proprietary platforms, including CaptiVateTM targeting T and B cells, and TolveraTM enabling next-generation cell-based RNA therapies. Catalyst Biosciences has a strategic partnership with CRISPR Therapeutics for the development of next-generation cure for hemophilia A. Additionally, Catalyst Biosciences is working on cancer therapies based on tumor-specific antibodies. The company has an internal development program, including an anti-CXCL12 antibody aiming to inhibit cancer cell growth in multiple clinical indications. The company also has a partnership with MilliporeSigma for the development of bispecific antibodies for the treatment of cancer. Catalyst Biosciences' business model primarily involves the development and sale of proprietary biological products and technologies. The company has an international patent portfolio and engages in partnerships with other companies to integrate its platform technologies into cell and gene therapy. Catalyst Biosciences receives research, development, licensing, and milestone payments from these partnerships. To expand its operations, Catalyst Biosciences has entered strategic partnerships with other biopharmaceutical companies such as Pfizer, CRISPR Therapeutics, and MilliporeSigma. These partnerships aim to expand and accelerate Catalyst Biosciences' research, development, distribution, and marketing activities. Another important component of Catalyst Biosciences' business model is financing research and development as well as clinical studies. The company has completed several public and private funding rounds to finance its development activities. Catalyst Biosciences has also utilized public funding sources such as Strategic Research Funding Programs (SRFPs) to further develop its platform technologies and products. Overall, Catalyst Biosciences has a unique and diverse business model focused on developing and distributing innovative therapeutic solutions for severe and rare medical needs. With its proprietary technologies and partnerships, the company is able to expand its research and development activities and bring its products to market faster.

What is the Catalyst Biosciences dividend?

Catalyst Biosciences pays a dividend of 1.43 USD distributed over payouts per year.

How often does Catalyst Biosciences pay dividends?

The dividend cannot currently be calculated for Catalyst Biosciences or the company does not pay out a dividend.

What is the Catalyst Biosciences ISIN?

The ISIN of Catalyst Biosciences is US14888D2080.

What is the Catalyst Biosciences WKN?

The WKN of Catalyst Biosciences is A2DLUK.

What is the Catalyst Biosciences ticker?

The ticker of Catalyst Biosciences is CBIO.

How much dividend does Catalyst Biosciences pay?

Over the past 12 months, Catalyst Biosciences paid a dividend of 1.43 USD . This corresponds to a dividend yield of about 8.01 %. For the coming 12 months, Catalyst Biosciences is expected to pay a dividend of 0.24 USD.

What is the dividend yield of Catalyst Biosciences?

The current dividend yield of Catalyst Biosciences is 8.01 %.

When does Catalyst Biosciences pay dividends?

Catalyst Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Catalyst Biosciences?

Catalyst Biosciences paid dividends every year for the past 0 years.

What is the dividend of Catalyst Biosciences?

For the upcoming 12 months, dividends amounting to 0.24 USD are expected. This corresponds to a dividend yield of 1.34 %.

In which sector is Catalyst Biosciences located?

Catalyst Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Catalyst Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Catalyst Biosciences from 1/12/2023 amounting to 0.24 USD, you needed to have the stock in your portfolio before the ex-date on 1/13/2023.

When did Catalyst Biosciences pay the last dividend?

The last dividend was paid out on 1/12/2023.

What was the dividend of Catalyst Biosciences in the year 2023?

In the year 2023, Catalyst Biosciences distributed 1.43 USD as dividends.

In which currency does Catalyst Biosciences pay out the dividend?

The dividends of Catalyst Biosciences are distributed in USD.

Other fundamentals and analyses of Catalyst Biosciences in the deep dive.

Our stock analysis for Catalyst Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Catalyst Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.